Is Vertex Pharmaceuticals Heading to $600?
Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy few years. The biotech company, known for its leadership in the cystic fibrosis (CF) treatment market, has proven its ability to broaden into other areas -- and win. The company gained approval for blood disorders treatment, Casgevy, and later for non-opioid pain drug, Journavx. And Vertex expanded its CF leadership with a new approval in that area, too.
Just recently, the company delivered more good news to investors: Povetacicept, its candidate for kidney disease IgA nephropathy, met its goals, and the company aims to submit it to regulators by the end of the month.
Considering the good news, is Vertex heading to $600? Let's find out.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
369,20 €
-0,14 %
Starke Bevorzugung von Vertex Pharmaceuticals Inc. in der Community mit ausschließlich Buy-Einschätzungen.
Ein Kursziel von 461 € für Vertex Pharmaceuticals Inc. könnte zu einer Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 369.2 € führen.
